Form D · Pharmaceuticals

Coeptis Therapeutics Inc.

Wexford, PA · CIK 0001819663

Offering snapshot reported Oct 12, 2021 · SEC filing

Reported sold
$5.52M
Offering amount: $9M
Investors reported
42
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 12, 2021
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$2.76M$5.52MMar 24, 2021: $171,000.00Mar 24, 2021Oct 12, 2021: $5,521,500.00Oct 12, 2021

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$171,000 → $5,521,500
  • Reported investors2 → 42

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 12, 2021Amendment$5,521,500$5,350,500vs Mar 24, 202142SEC filing
Jul 28, 2021Amendment$5,206,500No comparisonNot reportedSEC filing
Mar 24, 2021Initial$171,000No comparison2SEC filing
Feb 25, 2021Initial$0No comparison81SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-393300

Source: Form D, filed Oct 12, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Michael Handley Director
David Mehalick Director, Executive
Christine Sheehy Director, Executive
Daniel Yerace Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
105 Bradford Rd, Suite 420
Wexford, PA, 15090